Use of 0,01% atropine for the control of myopia in Ecuadorian children
DOI:
https://doi.org/10.47464/MetroCiencia/vol32/2/2024/22-27Keywords:
myopia, atropine, low concentration, high-myopia, refractive errors, progressionAbstract
Introduction: Myopia is the most common refractive disorder worldwide and has become one of the leading causes of preventable visual impairment. Atropine has been extensively studied as a drug for the control of myopia progression. Methods: A retrospective study was conducted on 68 myopic eyes treated with 0,01% atropine eye drops once a day between January 2016 to December 2023. Results: Myopia progression was reduced by 50% in patients treated with 0,01% atropine eye drops. Mild adverse effects were reported in 2,15% of cases and no serious adverse effects were seen. Conclusions: Atropine 0,01% reduced myopia progression in Ecuadorian children by 50%.
Downloads
References
Upadhyay A, Beuerman RW. Biological mechanisms of atropine control of myopia. Eye Contact Lens [Internet]. 2020;46(3):129–35. Disponible en: http://dx.doi.org/10.1097/icl.0000000000000677
Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology [Internet]. 2016;123(5):1036–42. Disponible en: http://dx.doi.org/10.1016/j.ophtha.2016.01.006
Zelman L, Molinari A, Balsa A, Angi M, Heede S, Iribarren R. Low prevalence of myopia in children from the Andean region in Ecuador. Oftalmol. clín. exp. [Internet]. 17 de diciembre de 2021 [citado 22 de marzo de 2024];14(4). Disponible en: https://revistaoce.com/index.php/revista/article/view/85
Jimenez JR, Bermudez J, Rubiño M, Gomez L, Anera RG. Prevalence of myopia in an adult population of two different ethnic groups in the Ecuadorian Amazon. Jpn J Ophthalmol [Internet]. 2004;48(2):163–5. Disponible en: http://dx.doi.org/10.1007/s10384-003-0041-z
Chua W-H, Balakrishnan V, Chan Y-H, Tong L, Ling Y, Quah B-L, et al. Atropine for the treatment of childhood myopia. Ophthalmology [Internet]. 2006;113(12):2285–91. Disponible en: http://dx.doi.org/10.1016/j.ophtha.2006.05.062
Chia A, Lu Q-S, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2. Ophthalmology [Internet]. 2016;123(2):391–9. Disponible en: http://dx.doi.org/10.1016/j.ophtha.2015.07.004
Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, et al. Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: Continued versus washout. Ophthalmology [Internet]. 2022;129(3):308–21. Disponible en: http://dx.doi.org/10.1016/j.ophtha.2021.10.002
Upadhyay A, Beuerman RW. Biological mechanisms of atropine control of myopia. Eye Contact Lens [Internet]. 2020;46(3):129–35. Disponible en: http://dx.doi.org/10.1097/icl.0000000000000677
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Mischell Lazaro Ordonio, Andrea Delia Molinari Szewald, Andrés David Salgado Miranda, Mónica Clemencia Vargas Buñay
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
